EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Monoclonal Gammopathy of Thrombotic Significance

Vasiliki Gkalea iD, Despina Fotiou iD, Meletios Athanasios Dimopoulos iD, Efstathios Kastritis iD

Cancers · 12.01.2023 · 15 (2) · 480

DOI: 10.3390/cancers15020480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.01.2023. Verfasst von Vasiliki Gkalea und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current review provides an overview of the thrombotic risk observed in patients with MG who do not otherwise require treatment. We discuss clinical and biomarker studies that highlight the heterogenous hemostatic profile observed in these patients and how knowledge has evolved over the past 20 years. Biomarker studies suggest shared biologic features between multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), which involves both hypercoagulability and platelet activation. Hemostatic abnormalities identified in MGUS patients cannot be translated into clinical practice as they lack correlation to clinical events. The prothrombotic phenotype of MGUS patients has not been ascertained yet, but novel data on coagulation markers are promising. We also review rare conditions associated with the thrombogenic properties of the monoclonal protein that predispose to arterial, venous or microthrombotic events and demonstrate that the M-protein can be linked to clinically significant thrombotic events. Cryoglobulinemia, cryofibrinogenemia, cryo-crystaloglobulinemia and MG-related antiphospholipid syndrome are reviewed. We propose the new umbrella term “monoclonal gammopathy of thrombotic significance” (MGTS) to refer to significant, recurrent thrombotic events in patients with MGUS that provide a rationale for targeting the underlying plasma cell clone. Identifying MGUS patients at high risk for thrombotic events is currently a challenge.

Schlagwörter

Stichwörter der Autor:innen

autoantibodiescoagulation biomarkerscryo-crystaloglobulinemiacryofibrinogenemiacryoglobulinsmonoclonal gammopathy of clinical significancemonoclonal gammopathy of undetermined significancemonoclonal immunoglobulinthrombosis

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece.

ORCID-Profile: Vasiliki Gkalea, Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Zitieren

APA

Gkalea, V., Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2023). Monoclonal Gammopathy of Thrombotic Significance. Cancers, 15(2), 480. https://doi.org/10.3390/cancers15020480

Vancouver

Gkalea V, Fotiou D, Dimopoulos MA, Kastritis E. Monoclonal Gammopathy of Thrombotic Significance. Cancers. 2023;15(2):480. doi:10.3390/cancers15020480

BibTeX
@article{Gkalea2023,
  author = {Gkalea, Vasiliki and Fotiou, Despina and Dimopoulos, Meletios Athanasios and Kastritis, Efstathios},
  title = {Monoclonal Gammopathy of Thrombotic Significance},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {480},
  doi = {10.3390/cancers15020480}
}
Kostenlos starten →